MetaCap

Innate Pharma S.A. (IPHA) vs Outlook Therapeutics (OTLK)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Innate Pharma S.A. (IPHA) has outperformed Outlook Therapeutics (OTLK) over the past year, losing 52.6% versus a loss of 79.3%. Over five years, IPHA leads with a -82.0% price change compared with -98.6% for OTLK. Innate Pharma S.A. is the larger company by market cap ($96.4 million vs $94.9 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

IPHA-52.56%OTLK-79.26%
+46%-25%-96%
Nov 21, 20251 yearNov 20, 2026
IPHA-82.77%OTLK-98.73%
+37%-34%-106%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

IPHA versus OTLK key metrics
MetricIPHAOTLK
Share price$0.8634$0.39
Market cap$96.44M$94.94M
1-day change-8.14%-2.74%
YTD return-50.66%-75.32%
1-year return-52.56%-79.26%
5-year return-82.01%-98.58%
EPS (TTM)$-0.59$-0.70
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$1.41M
Net income (latest FY)—$-62.42M
Gross margin—4.05%
Operating margin—-4744.25%
Net margin—-4416.22%
52-week high$2.71$2.54
52-week low$0.829$0.161
Distance from 52-week high-68.14%-84.63%
Analyst consensusbuynone
Avg. price target upside+826.57%+1189.74%
Average volume42.76K4.60M
Shares outstanding111.70M243.45M
Employees12017
SectorHealth CareHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)Biotechnology: Biological Products (No Diagnostic Substances)

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • IPHA has outperformed OTLK by 26.7 percentage points over the past year.

About Innate Pharma S.A.

IPHA stock →

Innate Pharma S.A. operates as a biotechnology company that develops immunotherapies for cancer patients in France and internationally.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 120 employees

About Outlook Therapeutics

OTLK stock →

Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic bevacizumab product formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 17 employees

IPHA vs OTLK FAQ

Which is bigger, Innate Pharma S.A. or Outlook Therapeutics?

Innate Pharma S.A. (IPHA) is larger, with a market capitalization of $96.44M compared with $94.94M for Outlook Therapeutics (OTLK).

Which stock has performed better over the past year, IPHA or OTLK?

IPHA returned -52.56% over the past 12 months, compared with -79.26% for OTLK (price return, excluding dividends). Past performance does not predict future results.

Are Innate Pharma S.A. and Outlook Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.

More comparisons